Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Dividends Calendar
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?

ExpreS2ion Biotechnologies – Presentation of Q2 interim report 2023

Af Michael FriisHead of Equities
ExpreS2ion Biotech Holding

Today, ExpreS2ion Biotechnologies released its Q2 2023 results and, more importantly, announced a review of its strategy, pipeline, and organization to materially extend the runway in a tight funding market. This includes, among others, a pause of the breast cancer candidate. With focus on the strategy announcement, the company’s CEO Bent Frandsen and CFO Keith Alexander presented the implications and potential effect of the strategy review, noting that this is in the first inning. 


ExpreS2ion Biotechnologies is a Danish biotechnology company, which focuses on the development of vaccines for diseases such as COVID-19, influenza, and breast cancer through the use of its non-viral Drosophila S2 cells-based expression system.

 

HC Andersen Capital receives payment from ExpreS2ion Biotechnologies for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis 13.30 PM 28-04-2023.

Xvivo, Audiocast, Q2'25
11.07.2025, 14.00 Xvivo Perfusion
Vitec Software Group, Audiocast, Q2'25
11.07.2025, 10.00 Vitec Software Group
Bravida, Webcast, Q2'25
11.07.2025, 09.30 Bravida Holding
Axfood, Audiocast, Q2'25
11.07.2025, 09.30 Axfood
Netel Group, Audiocast, Q2'25
11.07.2025, 09.00 Netel Holding
Vis alle videoer
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.